ES2393144T3 - Uso de riboflavina en el tratamiento de la hipertensión - Google Patents
Uso de riboflavina en el tratamiento de la hipertensión Download PDFInfo
- Publication number
- ES2393144T3 ES2393144T3 ES08715988T ES08715988T ES2393144T3 ES 2393144 T3 ES2393144 T3 ES 2393144T3 ES 08715988 T ES08715988 T ES 08715988T ES 08715988 T ES08715988 T ES 08715988T ES 2393144 T3 ES2393144 T3 ES 2393144T3
- Authority
- ES
- Spain
- Prior art keywords
- riboflavin
- blood pressure
- mthfr
- product
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0703514.0A GB0703514D0 (en) | 2007-02-23 | 2007-02-23 | Use of riboflavin |
| GB0703514 | 2007-02-23 | ||
| PCT/EP2008/001437 WO2008101724A1 (en) | 2007-02-23 | 2008-02-22 | Use of riboflavin in the treatment of hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2393144T3 true ES2393144T3 (es) | 2012-12-18 |
Family
ID=37945596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08715988T Active ES2393144T3 (es) | 2007-02-23 | 2008-02-22 | Uso de riboflavina en el tratamiento de la hipertensión |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20100324019A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2139488B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5577100B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101678030B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2679217C (cg-RX-API-DMAC7.html) |
| EA (1) | EA019281B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2393144T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0703514D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009009020A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008101724A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX358541B (es) * | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| CN103721259A (zh) * | 2014-01-07 | 2014-04-16 | 深圳奥萨医药有限公司 | 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物 |
| CN109295216A (zh) * | 2018-11-06 | 2019-02-01 | 宁波艾捷康宁生物科技有限公司 | 预测高血压个体化药物药效的snp位点和检测试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264601A (en) * | 1979-06-12 | 1981-04-28 | The Board Of Regents Of The University Of Oklahoma | Antihypertensive agents and their use in treatment of hypertension |
| ATE68704T1 (de) * | 1986-12-18 | 1991-11-15 | Bauer Kurt Heinz | Gegenueber lichteinfluss stabilisiertes nifedipin- konzentrat und verfahren zu seiner herstellung. |
| US6485959B1 (en) * | 1998-10-07 | 2002-11-26 | Cedars Sinai Medical Center | Cell preconditioning and cryopresevation medium |
| CN1136895C (zh) * | 2001-05-24 | 2004-02-04 | 魏振鸣 | 一种治疗冠心病的药物 |
| WO2006085128A1 (en) * | 2005-02-09 | 2006-08-17 | Wockhardt Limited | Cardiovascular therapeutic combinations |
| US7838526B2 (en) * | 2005-08-05 | 2010-11-23 | Esther Baldinger | Method of treating neurological disorders |
-
2007
- 2007-02-23 GB GBGB0703514.0A patent/GB0703514D0/en not_active Ceased
-
2008
- 2008-02-22 WO PCT/EP2008/001437 patent/WO2008101724A1/en not_active Ceased
- 2008-02-22 ES ES08715988T patent/ES2393144T3/es active Active
- 2008-02-22 EA EA200901145A patent/EA019281B1/ru not_active IP Right Cessation
- 2008-02-22 JP JP2009550246A patent/JP5577100B2/ja not_active Expired - Fee Related
- 2008-02-22 US US12/528,105 patent/US20100324019A1/en not_active Abandoned
- 2008-02-22 EP EP08715988A patent/EP2139488B1/en not_active Not-in-force
- 2008-02-22 CN CN2008800135209A patent/CN101678030B/zh not_active Expired - Fee Related
- 2008-02-22 CA CA2679217A patent/CA2679217C/en active Active
- 2008-02-22 MX MX2009009020A patent/MX2009009020A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US20100324019A1 (en) | 2010-12-23 |
| CA2679217C (en) | 2016-05-17 |
| CN101678030B (zh) | 2013-06-05 |
| EA019281B1 (ru) | 2014-02-28 |
| WO2008101724A8 (en) | 2009-10-08 |
| JP2010519235A (ja) | 2010-06-03 |
| JP5577100B2 (ja) | 2014-08-20 |
| CN101678030A (zh) | 2010-03-24 |
| GB0703514D0 (en) | 2007-04-04 |
| MX2009009020A (es) | 2010-02-17 |
| EP2139488B1 (en) | 2012-08-15 |
| EA200901145A1 (ru) | 2010-02-26 |
| EP2139488A1 (en) | 2010-01-06 |
| CA2679217A1 (en) | 2008-08-28 |
| WO2008101724A1 (en) | 2008-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2318517C2 (ru) | Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент | |
| TWI630924B (zh) | 使用包含微脂體伊立替康(irinotecan)的組合療法治療胰臟癌的方法 | |
| ES2981521T3 (es) | Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales | |
| Grünwald et al. | Practical management of everolimus-related toxicities in patients with advanced solid tumors | |
| JP2010518169A (ja) | 心血管疾患の処置のためのラノラジンの使用 | |
| US20190307791A1 (en) | Use of ferric citrate in the treatment of and the reduction of mortality and morbidity related to adverse cardiac events in chronic kidney disease patients | |
| Li et al. | Correlation of angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by angiotensin-converting enzyme inhibitor | |
| BR112021005518A2 (pt) | métodos para tratar distúrbios mieloproliferativos | |
| Trzos et al. | Myocardial infarction in young people | |
| CA3113376A1 (en) | Compositions for reducing serum uric acid | |
| KR20200013644A (ko) | 간세포 암종의 치료 | |
| KR20250078897A (ko) | 알도스테론 신타아제 저해제인 박스드로스타트를 이용한 고혈압 치료 방법 | |
| CA2679217C (en) | Use of riboflavin in the treatment of hypertension | |
| US20190201508A1 (en) | Methods for treating cancers using ace inhibitors, arb, or celecoxib and olmesartan | |
| JPH11507012A (ja) | 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療 | |
| US20220160739A1 (en) | Methods for treating subjects with chronic kidney disease | |
| WO2024173768A1 (en) | Compositions and methods of using eflornithine | |
| KR20080012896A (ko) | 췌장염 예방 및 치료제 | |
| Mizumura et al. | Vasovagal reaction and ischemic colitis following blood donation | |
| Liau et al. | Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients | |
| Villanueva et al. | Probable association between ziprasidone and worsening hypertension | |
| Mikhailova et al. | Pharmacokinetics of Angiotensin-Converting Enzyme Inhibitors in Elderly Patients with Arterial Hypertension | |
| MX2014012001A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek. | |
| Rolfo et al. | Adverse event management in anaplastic lymphoma kinase-positive non-small cell lung cancer | |
| Cacciola et al. | Effect of anagrelide on JAK2 mutational status in patients with essential thrombocythemia |